What did Ira Mellman and Axel Hoos discuss at IO360 2026?

They were featured in a fireside-chat-style podcast from the 2026 Immuno-Oncology 360° conference focused on what’s next for immuno-oncology. The article frames it as a leadership and strategy signal rather than a concrete business event, since no trial data, approvals, financing, or deal terms were disclosed.